SCHEMBL610088

SCHEMBL610088

CN(C)c1ccc(/C=C2/CCCC(C(=O)/C=C/c3ccc(N(C)C)c(O)c3)C2=O)cc1O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.43
APP P05067 6/20 0.42
MGAM O43451 1/20 0.36
GAA P10253 1/20 0.36
SI P14410 1/20 0.36
MGAM2 Q2M2H8 1/20 0.36
MITF O75030 1/20 0.35
HSP90AA1 P07900 1/20 0.35
PTGS2 P35354 1/20 0.35
MEN1 O00255 1/20 0.35
JUN P05412 1/20 0.35
MME P08473 1/20 0.35
NFKB1 P19838 1/20 0.35
KMT2A Q03164 1/20 0.35
NOD2 Q9HC29 1/20 0.35
EGFR P00533 2/20 0.35
EP300 Q09472 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
CYP1A2 P05177 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL610089 1.00 ACHE (0.43) ACHEAPPMGAMGAASI
SCHEMBL17503194 0.81 ACHE (0.60) ACHEMITFHSP90AA1PTGS2MEN1
SCHEMBL17693091 0.81 MEN1 (0.59) APPGAAPTGS2MEN1JUN
SCHEMBL610183 0.81 MEN1 (0.59) APPGAAPTGS2MEN1JUN
SCHEMBL610182 0.81 MEN1 (0.59) APPGAAPTGS2MEN1JUN
SCHEMBL610174 0.80 PSMB5 (0.43) ACHEHSP90AA1PTGS2MEN1JUN
SCHEMBL610173 0.80 PSMB5 (0.43) ACHEHSP90AA1PTGS2MEN1JUN
SCHEMBL608069 0.80 ACHE (0.56) ACHEAPPMGAMGAASI
SCHEMBL608070 0.80 ACHE (0.56) ACHEAPPMGAMGAASI
SCHEMBL22349310 0.78 MEN1 (0.56) APPGAAPTGS2MEN1JUN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120040976-A1 SMALL MOLECULE IMMUNOMODULATORS FOR ALZHEIMER'S DISEASE HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) 2012-02-16 US claimed
WO-2010068935-A2 SMALL MOLECULE IMMUNOMODULATORS FOR ALZHEIMER'S DISEASE HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) 2010-06-17 WO claimed
US-20120040976-A1 SMALL MOLECULE IMMUNOMODULATORS FOR ALZHEIMER'S DISEASE HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) 2012-02-16 US disclosed
WO-2010068935-A2 SMALL MOLECULE IMMUNOMODULATORS FOR ALZHEIMER'S DISEASE HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) 2010-06-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040976-A1 SMALL MOLECULE IMMUNOMODULATORS FOR ALZHEIMER'S DISEASE L1CAM, LY96, GMFG ACHE 18/4885APP 730/4885MGAM 2002/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.